Barclays Starts Pacira Pharmaceuticals (PCRX) at Equalweight
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $24.01 -1.44%
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
12 Buy, 15 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Barclays analyst Glen Santangelo initiates coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Equalweight rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $23.99 yesterday.
You May Also Be Interested In
- PharmaCorp Rx Inc. Announces Second Quarter 2026 Financial Results
- BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy
- Truist Securities Reinstates Pacira Pharmaceuticals (PCRX) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
